RPG Life Sciences Reports Q1 FY27 Results: Consolidated Net Profit Up 17% YoY to ₹30.76 Crore

RPG Group company RPG Life Sciences Limited (NSE: RPGLIFESCI | BSE: 508670) has released its standalone and consolidated unaudited financial results for the first quarter ended June 30, 2026 (Q1 FY27).

The pharmaceutical firm registered a strong performance for the quarter, driven by robust domestic sales and operational efficiencies. Consolidated net profit reached ₹30.76 crore, up 17.00% year-on-year (YoY) compared to ₹26.29 crore in the corresponding period of the previous fiscal year.

Key Financial Highlights (Q1 FY27 vs Q1 FY26 & Q4 FY26)

All monetary amounts are reported in ₹ lakhs as filed with stock exchanges (1 Crore} = 100 Lakhs).

CONSOLIDATED FINANCIAL OVERVIEW

   Revenue from Operations     Profit Before Tax (PBT)       Net Profit (PAT)
  -------------------------    -----------------------     --------------------
  Q1 FY27: ₹19,569             Q1 FY27: ₹4,146             Q1 FY27: ₹3,076
  Q4 FY26: ₹17,689             Q4 FY26: ₹4,020             Q4 FY26: ₹2,990
  Q1 FY26: ₹16,892             Q1 FY26: ₹3,543             Q1 FY26: ₹2,629

Consolidated Performance Breakdown

Revenue & Top-Line Metrics

Revenue from Operations: Stood at ₹19,569 lakh (~₹195.69 crore) in Q1 FY27, delivering a 15.85% YoY expansion compared to ₹16,892 lakh in Q1 FY26, and a 10.63% sequential growth over ₹17,689 lakh in Q4 FY26.

Other Income: Came in at ₹470 lakh (compared to ₹523 lakh in Q1 FY26 and ₹1,240 lakh in Q4 FY26).

Total Income: Reached ₹20,039 lakh (~₹200.39 crore), registering a 15.07% YoY increase over ₹17,415 lakh recorded in Q1 FY26.

Expenditure & Margin Analysis

Total expenses for the quarter rose to ₹15,893 lakh (~₹158.93 crore), up from ₹13,872 lakh in Q1 FY26:

Cost of Materials Consumed: ₹3,768 lakh (vs. ₹3,204 lakh in Q1 FY26).

Purchases of Stock-in-Trade: ₹3,953 lakh (vs. ₹3,306 lakh in Q1 FY26).

Employee Benefits Expense: ₹3,776 lakh (vs. ₹3,370 lakh in Q1 FY26).

Other Expenses: ₹4,649 lakh (vs. ₹3,973 lakh in Q1 FY26).

Depreciation & Amortisation: Controlled at ₹590 lakh (vs. ₹514 lakh in Q1 FY26).

Finance Costs: Stood minimal at ₹63 lakh (vs. ₹13 lakh in Q1 FY26).

Profitability & Earnings Per Share

Profit Before Tax (PBT): Expanded 17.02% YoY to ₹4,146 lakh (~₹41.46 crore), compared to ₹3,543 lakh in Q1 FY26.

Tax Expenses: Totaled ₹1,070 lakh (Current tax: ₹1,082 lakh; Deferred tax credit: ₹12 lakh).

Net Profit After Tax (PAT): Rose to ₹3,076 lakh (~₹30.76 crore), compared to ₹2,629 lakh in Q1 FY26 and ₹2,990 lakh in Q4 FY26.

Consolidated EPS: Basic and diluted EPS improved to ₹18.60 per share (Face value of ₹8/- each), compared to ₹15.90 in Q1 FY26.

Standalone Financial Summary

RPG Life Sciences' standalone results closely matched its consolidated performance:

Revenue from Operations: ₹19,569 lakh (~₹195.69 crore), up 15.85% YoY.

Total Income: ₹19,985 lakh (~₹199.85 crore).

Profit Before Tax (PBT): ₹4,121 lakh (~₹41.21 crore), growing 16.31% YoY.

Net Profit After Tax (PAT): ₹3,057 lakh (~₹30.57 crore), expanding 16.28% YoY from ₹2,629 lakh in Q1 FY26.

Standalone EPS: Stood at ₹18.49 per share.

Balance Sheet Profile

Paid-up Equity Share Capital: Unchanged at ₹1,323 lakh (Face value ₹8/- per equity share).

Other Equity (As of March 31, 2026): Stood at ₹59,212 lakh (Consolidated) and ₹59,214 lakh (Standalone).

Commenting on the results and business outlook, Mr. Ashok Nair, Managing Director, RPG Life Sciences Ltd., said: "We have started FY27 on a strong note continuing our track record of market-beating performance and growth. Our Domestic Formulations business continued to outperform the market and helped the company enter the Top 50 ranking in the Indian Pharma Market, an important milestone in our growth journey.

Going forward, we remain focused on strengthening our international presence through market expansion and new customer onboarding along with scaling up our API operations that can drive the next wave of growth of us. Backed by strong balance sheet, healthy profitability and continued investment in talent, we remain confident of sustaining our growth momentum in the long-term."

Shares of RPG Life Sciences Limited was last trading in BSE at Rs. 2777.65 as compared to the previous close of Rs. 2846.90. The total number of shares traded during the day was 892 in over 161 trades.

The stock hit an intraday high of Rs. 2891.45 and intraday low of 2770.00. The net turnover during the day was Rs. 2498507.00.

Source : Equity Bulls

Keywords

RPGLifeSciences INE105J01010 Pharmaceuticals Q1FY27 Q1FY2027 ResultUpdate